TwichView-guided Atricurium Dose Adjustment Trial
NCT: NCT07807046 · RECRUITING
Brief Summary
The goal of this clinical trial is to learn if using a monitor that measures muscle response can lower the amount of muscle relaxant medicine needed in adults who are treated in an intensive care unit (ICU) and need a continuous drip of a muscle relaxant called atracurium for more than 48 hours. The main questions it aims to answer are: Does using the monitor lower the infusion rate and total amount of atracurium given over 72 hours? Does using the monitor lower the complications related to atracurium use? Researchers will compare a group whose dose is guided by a muscle response monitor, aiming for a moderate level of muscle relaxation, to a group whose dose is guided by the usual bedside checks, to see if the monitor lowers the amount of medicine needed while keeping the same quality of care. Participants will: Receive atracurium as a continuous drip as part of their usual ICU treatment Have a small sensor placed on the wrist and hand to measure muscle response, if they are in the monitor group Be checked regularly by a nurse and a respiratory therapist, who will adjust the dose following a written plan Be observed closely for 72 hours, then followed until they leave the hospital .
Frequently Asked Questions
What is TwichView-guided Atricurium Dose Adjustment Trial?
TwichView-guided Atricurium Dose Adjustment Trial is a clinical trial registered under NCT07807046. Current status: RECRUITING.
What is the status of NCT07807046?
The current status of NCT07807046 (TwichView-guided Atricurium Dose Adjustment Trial) is: RECRUITING.
When did TwichView-guided Atricurium Dose Adjustment Trial start?
TwichView-guided Atricurium Dose Adjustment Trial started on 2026-08-19.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.